Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

1.8K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.8K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

44
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
44
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

28
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
28

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Practical Comparison of Two- and Three-Phase Bearingless Permanent Magnet Slice Motors for Blood Pumps.

Actuators·2026
Same author

Utility of Right Ventricular Mass Ratios in Recipients With Pulmonary Hypertension: A United Network for Organ-Sharing Database Analysis.

Clinical transplantation·2026
Same author

Ideal Body Weight Ratio for Donor-to-Recipient Size Matching in Heart Transplantation.

Clinical transplantation·2025
Same author

Heart Allograft Utilization Rates Following Donation After Circulatory Death Compared to Donation After Brain Death in the Ideal Heart Donor.

Clinical transplantation·2025
Same author

Microaxial Support as a Bridge to Repair in Post-Myocardial Infarction Ventricular Septal Rupture: A Systematic Review and Patient-Level Analysis.

Artificial organs·2025
Same author

Report on the 30th Annual Meeting of the International Society for Mechanical Circulatory Support (ISMCS).

Artificial organs·2025

Related Experiment Video

Updated: Sep 14, 2025

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
08:49

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

9.5K

Activation Mechanism Design for a Dual-Blood Pumping System for Pediatric Heart Failure.

Thomas C Palazzolo1, Giselle C Matlis1, Ethan Pastor1

  • 1BioCirc Research Laboratory, School of Biomedical Engineering, Science, and Health Systems, Drexel University, Philadelphia, Pennsylvania, USA.

Artificial Organs
|July 24, 2025
PubMed
Summary

This study introduces a novel double-blood pump ventricular assist device (VAD) for pediatric heart failure, demonstrating a low blood damage potential and effective in-situ actuation for improved patient outcomes.

Keywords:
pediatric blood pumppediatric circulatory supportpediatric total artificial heartventricular assist device

More Related Videos

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

3.7K
Implantation of Total Artificial Heart in Congenital Heart Disease
07:27

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

24.8K

Related Experiment Videos

Last Updated: Sep 14, 2025

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
08:49

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

9.5K
Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

3.7K
Implantation of Total Artificial Heart in Congenital Heart Disease
07:27

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

24.8K

Area of Science:

  • Biomedical Engineering
  • Pediatric Cardiology
  • Medical Device Development

Background:

  • Pediatric end-stage heart failure (HF) presents unique treatment challenges.
  • Current mechanical circulatory support (MCS) devices show suboptimal outcomes in children compared to adults.
  • A need exists for advanced MCS solutions tailored to pediatric patients.

Purpose of the Study:

  • To develop and evaluate a novel double-blood pump ventricular assist device (VAD) for pediatric patients.
  • To create a single-device solution offering effective support across various pediatric age ranges.
  • To design an innovative activation mechanism for the secondary pump based on increased cardiac demand.

Main Methods:

  • Utilized virtual studies to refine the activation mechanism design based on functional and anatomical constraints.
  • Conducted iterative design improvements to meet performance targets.
  • Performed in-vitro functional, hydraulic, and hemolytic flow loop testing to assess device performance and blood compatibility.

Main Results:

  • The developed prototype demonstrated effective and repeatable in-situ actuation.
  • The device provided leak-free support at physiological pressures and flows.
  • Hemolytic testing indicated a low potential for blood damage.

Conclusions:

  • The study validates the proposed activation mechanism for the novel VAD.
  • The findings support the continued translational development of the Drexel Double Dragon VAD for pediatric application.